Lung Non-Squamous Non-Small Cell Carcinoma

subtype

Identifier: CI-CAN-00005826
Entity page: /cancer/lung-non-squamous-non-small-cell-carcinoma ↗
Edges: 989

Neighbours: 15 genes19 drugs10 trials
Drawn: 44 of 44 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Lung Non-Squamous Non-Small Cell Carcinoma approved for …APPROVED_FOR10 of 10
← approved for	Pemetrexedsmall_molecule 7 source records aggregated	supports	FDA ORIG	Lung Non-Squamous Non-Small Cell Carcinoma	7	Regulatory	openfda	graph →
← approved for	Bevacizumabmonoclonal_antibody

Lung Non-Squamous Non-Small Cell Carcinoma altered in cohorts of …ALTERED_INderived15 of 492show all (up to 200)
← altered in cohorts of	RYR2 413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 11 cohorts	—	—	Lung Adenocarcinoma	11	Observed	gdc	graph →
← altered in cohorts of	FLG 406 / 573 cases (71 %) · ssm · TCGA-LUAD · largest of 9 cohorts	—	—	Lung Adenocarcinoma	9	Observed	gdc	graph →
← altered in cohorts of	USH2A 402 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 11 cohorts	—	—	Lung Adenocarcinoma	11	Observed	gdc	graph →
← altered in cohorts of	PRPF3 35 / 50 cases (70 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	SPTA1 400 / 573 cases (70 %) · ssm · TCGA-LUAD · largest of 11 cohorts	—	—	Lung Adenocarcinoma	11	Observed	gdc	graph →
← altered in cohorts of	FCGR3A 60 / 87 cases (69 %) · ssm · APOLLO-LUAD	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	HSPA6 60 / 87 cases (69 %) · ssm · APOLLO-LUAD · largest of 2 cohorts	—	—	Lung Adenocarcinoma	2	Observed	gdc	graph →
← altered in cohorts of	ANP32E 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	APH1A 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	C1orf54 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CA14 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CIART 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	CTXND2 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MRPS21 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →
← altered in cohorts of	MTX1 34 / 50 cases (68 %) · ssm · CDDP_EAGLE-1	—	—	Lung Adenocarcinoma	1	Observed	gdc	graph →

Lung Non-Squamous Non-Small Cell Carcinoma altered in cohorts of …ALTERED_INderived15 of 492show all (up to 200)

← altered in cohorts of

RYR2

413 / 573 cases (72 %) · ssm · TCGA-LUAD · largest of 11 cohorts

—

Lung Adenocarcinoma

Observed

Lung Non-Squamous Non-Small Cell Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 79show all (up to 200)
→ investigated in trials for	Carboplatinsmall molecule 55 trials (21 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	55	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall_molecule 54 trials (17 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	54	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal_antibody 42 trials (6 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 40 trials (11 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	40	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 34 trials (6 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinibsmall molecule 30 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal_antibody 27 trials (15 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 20 trials (7 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 14 trials (7 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 13 trials (3 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinib Hydrochloridesmall molecule 10 trials (1 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Gefitinibsmall molecule 10 trials (0 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Osimertinibsmall molecule 8 trials (2 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Tislelizumabmonoclonal_antibody 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Durvalumabmonoclonal antibody 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	5	Observed	clinicaltrials	graph →

Lung Non-Squamous Non-Small Cell Carcinoma studied in …STUDIED_INderived10 of 408show all (up to 200)
→ studied in	NCT04267848Phase 3 · recruiting Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) · condition mapped ONTOLOGY_EXACT · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07489066Phase 2 · recruiting Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC · condition mapped ALIAS · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04181060Phase 3 · recruiting Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer · condition mapped CURATED_BROADER · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06491862recruiting RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil · condition mapped ALIAS · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06627647Phase 3 · recruiting A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC · condition mapped ALIAS · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03965689Phase 2 · active not recruiting Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy · condition mapped CURATED_BROADER · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06151574Phase 3 · active not recruiting Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment · condition mapped ALIAS · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03793179Phase 3 · active not recruiting Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03391869Phase 3 · active not recruiting Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer · condition mapped ONTOLOGY_EXACT · 408 trials mapped (118 active)	—	—	Lung Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05017025Phase 1/Phase 2 · completed Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer · condition mapped CURATED_BROADER · 408 trials mapped (118 active)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains